NewAmsterdam Pharma (NAMS) said Tuesday a phase 3 trial assessing obicetrapib in people with established atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia reached its primary endpoint.
The company's shares surged 35% in recent premarket activity.
The primary endpoint was the least-squares mean of the percent change in LDL-C from baseline to day 84 for obicetrapib 10 milligrams compared with placebo, the company said, adding the primary goal was reached with "statistical significance with an LDL-C reduction of 33%."
Also, obicetrapib was well-tolerated, with safety results, including blood pressure, comparable to placebo, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.